Fig 1: Knocking down RPL39 mitigated the abnormal increase in right ventricular contractility. (a) Right ventricular pressure volume loop (PV-loop) in male-vehicle, male-shRNA, female-vehicle, and female-shRNA groups; the horizontal and vertical coordinates represent the changes of right ventricular volume and pressure from end-systolic to end-diastolic, respectively. (b) Red and blue lines represent the right ventricular systolic PV relationship (ESPVR) and diastolic PV relationship (EDPVR) in male-vehicle, male-shRNA, female-vehicle, and female-shRNA groups. The slopes of ESPVR and EDPVR were positively correlated with right ventricular systolic capacity and diastolic capacity, respectively.
Fig 2: The subgroups of macrophages in male and female PAH samples. (a) The gene expression level of RPL39 between male and female PAH samples. (b) The UMAP plot showed the subgroups of macrophages in male and female PAH samples. (c) The ratio of each subgroup of macrophages in male and female PAH samples.
Fig 3: Knockdown RPL39 attenuated the sex differences in PAH. (a) RPL39 knockdown narrowed the degree of difference in hemodynamic parameters between male- and female-shRNA groups. (b–c) RPL39 knockdown narrowed the degree of difference in vascular wall thickness between male- and female-shRNA groups. Data in the box plots are presented as mean ± SD. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, and ∗∗∗∗p < 0.0001.
Fig 4: Knockdown RPL39 alleviated PAH by suppressing cell proliferation of macrophages. (a–b) The effect of shRNA on knocking down the protein level of RPL39 in male and female macrophages, shRNA versus vector, n = 3; (c) the effect of RPL39 knockdown on the proliferation level of male and female macrophages, shRNA versus vector, n = 6; (d) body weight; (e) mean pulmonary arterial pressure, mPAP; (f) right ventricular hypertrophy index; (g) pulmonary vascular resistance, PVR; (h) stroke volume, SV; (i) cardiac output, CO; (j) ejection fraction, EF; (k) effective arterial elastance, Ea; (l) end-systolic volume, Ves; (m) end-diastolic volume, Ved; (n) end-systolic pressure, Pes; (o) end-diastolic pressure, Ped; (p) end-systolic pressure–volume relationship, ESPVR; (q) end-diastolic pressure–volume relationship, EDPVR; (r-s) the protein level of RPL39 in male and female PAH rats with and without shRNA treatment, shRNA versus vehicle, n = 5; data in the box plots are presented as mean ± SD. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, and ∗∗∗∗p < 0.0001.
Supplier Page from Abcam for Anti-RPL39 antibody